GCG and type 2 diabetes mellitus: Recently, a once weekly GLP-1/glucagon co-agonist, LY3305677 (IBI362) has completed phase 1 trials with reported mean bodyweight loss of 4.8–6.4% in overweight and obese adults [87] and improved glycaemic control in patients with T2DM [88].